Citation: | TAO Run, GUAN Han, LIU Yan-shen, ZHOU Wen-sheng. Multivariate analysis of prognosis and nomogram construction of cystadenocarcinoma based on SEER database[J]. Chinese Journal of General Practice, 2021, 19(4): 674-678. doi: 10.16766/j.cnki.issn.1674-4152.001891 |
[1] |
NING J Z, YU W M, CHENG F, et al. MiR-425 promotes migration and invasion in bladder cancer by targeting Dickkopf 3[J]. J Cancer, 2020, 11(12): 3424-3432. doi: 10.7150/jca.40233
|
[2] |
江明友, 万明发, 洪钟亮. 尿液BLCA-4与BLCA-1水平在膀胱癌诊断及复发检测中的价值[J]. 中华全科医学, 2018, 16(4): 570-572. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201804019.htm
|
[3] |
MOSCHINI M, D'ANDREA D, KORN S, et al. Characteristics and clinical significance of histological variants of bladder cancer[J]. Nat Rev Urol, 2017, 14(Suppl 2): 651-668. http://www.nature.com/articles/nrurol.2017.125.pdf
|
[4] |
江明友, 万明发, 洪钟亮. 尿液BLCA-4与BLCA-1水平在膀胱癌诊断及复发检测中的价值[J]. 中华全科医学, 2018, 16(4): 570-572. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201804019.htm
|
[5] |
VASUDEVAN G, BISHNU A, SINGH B M K, et al. Bladder adenocarcinoma: a persisting diagnostic dilemma[J]. J Clin Diagn Res, 2017, 11(3): ER01-ER04. http://jcdr.net/articles/PDF/9536/24590_CE[Ra1]_F(DK)_PF1(SY_RK)_PFA(P)_PF2(P_NESY).pdf
|
[6] |
SIEGEL REBECCA L, MILLER KIMBERLY D, JEMAL AHMEDIN. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
|
[7] |
郭晓雪, 刘云鹤, 李文涛, 等. 膀胱原发性腺癌1例报告并文献复习[J]. 亚太传统医药, 2018, 14(7): 124-125. https://www.cnki.com.cn/Article/CJFDTOTAL-YTCT201807045.htm
|
[8] |
许晖阳, 王道虎. 膀胱腺癌的诊治进展[J]. 国际泌尿系统杂志, 2017, 37(2): 271-273. doi: 10.3760/cma.j.issn.1673-4416.2017.02.032
|
[9] |
SZARVAS T, MÔDOS O, NIEDWOROK C, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1, 010 cases[J]. Urol Oncol, 2016, 34(9): 388-398. doi: 10.1016/j.urolonc.2016.04.012
|
[10] |
顾伟平, 徐耀庭, 李杜渐, 等. 二次电切结合吉西他滨膀胱灌注化疗治疗肌层浸润性膀胱癌[J]. 中国临床研究, 2018, 31(9): 1215-1219. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201809016.htm
|
[11] |
KIM M J, KIM Y S, OH S Y, et al. Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee[J]. Korean J Intern Med, 2018, 33(2): 383-390. doi: 10.3904/kjim.2015.162
|
[12] |
TSIRONIS G, BAMIAS A. Treating bladder adenocarcinoma[J]. Transl Androl Urol, 2018, 7(Suppl 6): S699-S701.
|
[13] |
翟天元, 罗彬杰, 贾占奎, 等. 53例膀胱腺癌的临床特征及预后相关因素分析[J]. 实用医学杂志, 2018, 34(14): 2393-2397. doi: 10.3969/j.issn.1006-5725.2018.14.028
|
[14] |
NATALE C, LEINWAND Z G, CHIANG J, et al. Reviewing the demographic, prognostic, and treatment factors of primary adenocarcinoma of the bladder: a seer population-based study[J]. Clin Genitourin Cancer, 2019, 17(5): 380-388. doi: 10.1016/j.clgc.2019.06.010
|
[15] |
JIN D, QIU S, JIN K, et al. Signet-Ring cell carcinoma as an independent prognostic factor for patients with urinary bladder cancer: a population-based study[J]. Front Oncol, 2020, 10: 653. doi: 10.3389/fonc.2020.00653
|
[16] |
ZHOU Z, KINSLOW C J, WANG P, et al. Clear cell adenocarcinoma of the urinary bladder is a glycogen-rich tumor with poorer prognosis[J]. Clin Med, 2020, 9(1): 138. http://www.researchgate.net/publication/338379928_Clear_Cell_Adenocarcinoma_of_the_Urinary_Bladder_Is_a_Glycogen-Rich_Tumor_with_Poorer_Prognosis
|
[17] |
WANG J W, WU Y, HE W Y, et al. Nomogram for predicting overall survival of patients with bladder cancer: A population-based study[J]. Int J Biol Markers, 2020, 35(2): 29-39. doi: 10.1177/1724600820907605
|
[18] |
CUMBERBATCH M G K, JUBBER I, BLACK P C, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018[J]. Eur Urol, 2018, 74(6): 784-795. doi: 10.1016/j.eururo.2018.09.001
|